Anti-inflammation heralds the future of CV medicine
Video navigation menu
- Residual inflammatory risk 0:42
- Findings from the CANTOS trial 1:57
- Findings with colchicine in patients with chronic atherosclerosis 3:11
- Colchicine in those with ACS and acute MI 7:31
- Anticipated guideline recommendations 11:25
Do you agree that the time has come to give colchicine to patients with stable atherosclerotic disease?
This video was recorded in response to a recent publication of a subanalysis of COLCOT in Eur Heart J.
Dr. Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: